One eye of rd12 mice received a sub-retinal injection of a vector carrying normal human RPE65 cDNA at post-natal day 18, and at 6-and 13-months of age. Electroretinograms (ERGs) and visual-evoked potentials (VEPs) were recorded to luminance, and to spatially and temporally modulated stimuli to assess the consequences of delayed treatment on visual pathway function. Early treatment resulted in better overall retinal rescue and better rescue of cone-mediated function. VEPs to low temporal frequency luminance modulation were well preserved at all but the oldest treatment age and corresponded to predictions based on the amount of retinal rescue. In contrast, VEPs to high frequency spatially and temporally modulated stimuli were impaired even at the earliest age. These results provide further support that early treatment in human LCA will have the most hope for optimal visual performance.
Introduction
Mutations in the RPE65 gene cause the early onset retinal disease Leber Congenital Amaurosis (LCA). The RPE65 protein is the isomerase responsible for the conversion of all-trans retinaldehyde (all-trans retinal) to photoactive 11-cis retinaldehyde (11-cis retinal) and is essential for normal function of the visual cycle (Jin, Li, Moghrabi, Sun, & Travis, 2005) . Disruption of the RPE65 gene results in the accumulation of all-trans-retinyl esters and the reduction of rhodopsin in the rod photoreceptor outer-segment. In humans and animals, the absence of rhodopsin leads to severe retinal abnormalities (Redmond et al., 1998; Thompson et al., 2000) . Clinically, LCA is characterized as an early onset and severe form of inherited retinal dystrophy with features of retinal pigmentary degeneration, night blindness and severely compromised or absent rod and cone electroretinographic (ERG) signals (Thompson et al., 2000) .
Attempts to rescue the normal phenotype in animal models of LCA using gene replacement therapy and pharmaceutical strategies have proven successful (Acland et al., 2005; Dejneka et al., 2004; Lai et al., 2004; Pang et al., 2006; Van Hooser et al., 2000) . A naturally occurring canine model, the Swedish Briard beagle, shows almost total visual impairment at birth as a result of a homozygous 4 base-pair deletion in exon 5 of the canine RPE65 gene (Veske, Nilsson, Narfstrom, & Gal, 1999) . Gene therapy using a rAAV vector carrying a wild-type canine RPE65 cDNA restored retinal function in this animal model (Acland et al., 2001) . Gene replacement therapy in a targeted knockout mouse (Rpe65 ¡/¡tm1Tmr ) model of LCA has also been successful (Lai et al., 2004) . More recently, rAAV-mediated RPE65 gene delivery to a naturally occurring mouse model of human LCA, the rd12 mouse (Pang et al., 2005a) , also successfully restored retinal biochemistry and function (Pang et al., 2006) .
Gene replacement therapy performed early in the course of the disease seems to hold the most promise of success. Delivery of the human RPE65 cDNA to retinal pigment epithelium cells of Rpe65 ¡/¡tm1Tmr homozygous mouse fetuses resulted in ERG b-wave thresholds that were near normal, and amplitudes that were sizeable, although abnormal, and when delivered at 1-2.5 months post-natal, was about 80% successful by ERG when assayed two months later (Dejneka et al., 2004) . rd12 mice injected at post-natal day 14 (P14) with a rAAV5-CBA-hRPE65 vector resulted in RPE65 expression over large areas of RPE, improved rhodopsin levels, and ERG signals that were approximately 66% of normal when assayed at 7-months of age (Pang et al., 2006) . However, gene therapy at advanced-disease stages appears to be far less successful. When treated at 17-24 months of age, gene replacement therapy in Rpe65 ¡/¡tm1Tmr homozygous mice resulted in a statistical improvement in ERG responses in only 4 of 25 mice (16%) and retinal biochemistry was restored in only 5 of 17 mice (29%) (Jacobson et al., 2005) . In addition, when treated at early ages, the extent of retinal biochemical and functional rescue appears to be sustainable for at least seven months in the rd12 mouse model of LCA (Pang et al., 2005a) and up to Wve years in the Briard dog (Acland et al., 2005; Narfstrom et al., 2003b) .
Collectively, the studies cited above support early intervention as having the most hope for signiWcant retinal rescue, both in terms of the number of eyes rescued and the amount of retina that is restored. However, the full phenomenon of vision is deWned not only by an intact retinal response but also by the integrity of cells and neural connections throughout the visual pathway from the retina to the primary visual cortex. The interaction of neural cells and information processing throughout the visual system deWne complex visual abilities, such as spatial and temporal resolution, and luminance and color discrimination. These visual abilities are reWned during development and depend on neural activity initiated at the level of the retina. In humans and animals, severe functional deWcits are known to occur as a result of depriving or limiting sensory input to these visual channels (see, for example, (JeVrey, Birch, Stager, Stager, & Weakley, 2001; Lewis, Maurer, & Brent, 1986; Lickey, Pham, & Gordon, 2004; Prusky, West, & Douglas, 2000) ).
One method of evaluating the functional integrity of the visual pathway is to record visual-evoked potentials (VEPs). In the studies reported here, we examined several aspects of cortical visual function using the VEP in the rd12 mouse model of LCA after gene replacement therapy to restore retinal function. Gene therapy was performed at post-natal day 18 (P18), at 6-months, and at 13-months of age, and our main goal was to determine the consequences of delayed treatment on cortical visual function.
Materials and methods

Mice
The rd12 mutant mouse, originally discovered at the Jackson Laboratory, was used in these studies (Pang et al., 2005a) . The rd12 mutation is caused by a nonsense mutation in exon 3 of the Rpe65 gene. Functional and biochemical studies conWrm that vitamin A metabolism and visual processing are disrupted in the rd12 mouse. Retinal function measured with the ERG is non-detectable at the earliest ages (1-month) except at the brightest stimulus intensities, while retinal morphology remains relatively intact for up to 7-8 months, although retinal "voids" begin to appear in the photoreceptor architecture as early as 6-weeks of age (Pang et al., 2005a 
Gene therapy
The rd12 mice were treated with a serotype 5 recombinant adenoassociated virus (rAAV5) vector carrying a normal human RPE65 cDNA injected sub-retinally at post-natal day 18 (P18) (N D 4), at 6-months (N D 4), and at 13-months of age (N D 1). Methods for generating treatment vectors have been described previously (Pang et al., 2006) .
Rhodopsin measurements
To determine if rhodopsin is regenerated in treated rd12 eyes, we puriWed pigment from eyecup lysates from the treated and untreated eyes of rd12 mice and from age-matched C57BL/6J control mice by immunoaYnity chromatography as previously described (Pang et al., 2006) .
Visual function tests
All visual function tests were performed two months after gene replacement therapy. The ERG and VEP were used to evaluate the status of retinal and cortical visual function, respectively. A normal VEP requires an intact visual pathway from the retina to the primary visual cortex and the relationship between ERG and VEP signals is a powerful tool to evaluate the functional integrity of cells throughout the visual pathway (Ridder, III & Nusinowitz, 2006) . Except for the placement of the recording electrode (cornea for the ERG; visual cortex for the VEP), stimuli were identical for both procedures. Intensityresponse functions were determined for rod-mediated vision, temporal tuning functions were derived under both dark-and light-adapted conditions to estimate critical Xicker fusion frequencies (CFFs), and conemediated responses to spatially modulated stimuli were measured with the sweep VEP to determine visual acuity. Methods for recording ERGs and VEPs in the mouse, and for estimating response parameters, have been described (Ridder, III & Nusinowitz, 2006) . Each mouse was examined with a slit lamp before and after testing to ensure the absence of media opacities. In addition, a custom made rigid gas-permeable contact lens was placed on the corneal surface during testing with pattern stimuli to eliminate transient cataract formation (Ridder, III & Nusinowitz, 2002 .
Results
Rhodopsin measurements
The UV-visible spectra of the eluted samples are shown in Fig. 1 for representative mice treated at P18, and at 6-and 13-months. The normal max of rhodopsin visual pigment (500 nm) was seen in the treated rd12 eyes at each age of treatment, whereas the untreated eye showed no absorption in the 500-nm region. The UV spectra also detected the puriWed opsin protein peak at a max of 280 nm in treated eyes. Compared to wild-type controls, the absorption spectrum from the treated rd12 eyes indicated that rhodopsin was restored to about 50% of the normal level for the P18 group, 30% for the mice treated at 6-months, and 23% for the single mouse treated at 13-months.
Rod ERG and VEP intensity-response functions
ERGs
ERG intensity-response (I-R) functions obtained under dark-adapted conditions are shown in Fig. 2A for the normal controls (n D 4) and for the rd12 eyes treated at P18 (n D 4), and at 6-(n D 4) and 13-(n D 1) months of age. Each response function was Wtted with a Naka-Rushton equation to estimate V max , the saturated amplitude, and k, the semi-saturation intensity. The response functions for each of the three groups of treated rd12 eyes are displaced downward from normal controls (Wlled circles) consistent with partial restoration of retinal function in these eyes. Untreated control eyes (open diamonds) show detectable, although severely abnormal, responses at only the highest stimulus intensities. Fig. 1 . Representative UV-visible spectrum of immunoaYnity-puriWed rhodopsin samples from the three ages of treatment. AYnity-bound rhodopsin has a max of approximately 500 nm in samples from normal C57BL/6 (controls; heavy lines) and AAV5-CBA-hRPE65-treated rd12 retina (thin lines), but is undetectable from untreated rd12 retinas (dashed lines).
Fig. 2. Dark-adapted intensity-response functions for ERGs (A) and VEPs (B)
. Open circles, squares, and triangles show the data from rd12 mice treated at P18, 6-months, and 13-months, respectively, compared to normal controls (Wlled circles). Measurements were made 2-months post-treatment. Error bars are §1 Standard Error (SE). In 2B, dashed lines are the predicted VEP intensity-response functions for the three groups of mice estimated from the extent of retinal rescue (see text for details).
The saturated (V max ) amplitude ( §SE) for the normal controls and for the three rd12 treatment groups, are 302.8 ( §26.8), 145.4 ( §14.3), 116.0 ( §8.44), and 91.3 V, respectively. Compared to the normal data, the change in V max suggests a functional recovery of about 48% for the rd12 mice treated at P18, 38% for the mice treated at 6-months, and 30% for the single mouse treated at 13-months. The estimate for k, the semi-saturation intensity, was 0.015 ( §0.0056), 0.0211 ( §0.006), 0.067 ( §0.026), and 0.044 scotopic td-s, for normal mice, and mice treated at P18, and at 6-and 13-months, respectively. (The mouse treated at 3-months is not representative of the level of treatment success at this age and was one of a few that showed signiWcant retinal rescue. This mouse was included in this study to examine the eVects on cortical function after a relatively long period of limited retinal input, which was the primary goal of this study.)
VEPs
VEP intensity-response (I-R) functions are shown in Fig. 2B . V max and k were estimated for each response function as described above. The V max amplitude ( §SE) for the normal controls and the rd12 mice treated at P18, and at 6-and 13-months, are 56.3 ( §10.8), 29.5 ( §6.5), 19.7 ( §3.43), and 12.4 V, respectively. Compared to the normal VEP data, the saturated amplitude (V max ) suggests a level of cortical function of about 52% at P18, 35% at 6-months, and 22% at 13-months. The estimates for k for the four groups of mice, are 0.0075 ( §.002), 0.0147 ( §0.009), 0.182 ( §0.166), and 0.29 scotopic td-s, respectively. The shift in k between the P18 and 6-months treatment groups was not statistically diVerent for ERG measurements (t D 1.626, p D 0.082) or for the VEP measurements (t D 1.47, p D 0.10), although there was a trend in the direction of reduced sensitivity (higher values of k) in the VEP measurements over this age range. The change in k in the VEP measurements for the mouse treated at 13-months was much greater than that observed for the ERG measurements when compared to the earlier treatment ages, suggesting a loss of function of the visual pathway for this mouse. Fig. 2B as dashed lines are the predicted VEP response functions that were derived, as a Wrst approximation, by scaling the normal VEP intensity-response function by the amount of retinal rescue for each group. The actual data agree well with the predicted response functions at P18 and at 6-months. The data for the 13-month treatment mouse are more variable and tend to fall below the predicted response function at most stimulus intensities. Nevertheless, the correspondence between the actual and predicted response functions suggests relative preservation of visual pathway function for all but the oldest treatment age in the processing of low temporal frequency luminance modulations.
Shown in
ERG and VEP temporal-response functions
ERGs
Dark-adapted ERG temporal-response functions are shown in Fig. 3A . The response function for normal mice (Wlled circles) is consistent with a low-pass Wlter as previously described (Ridder, III & Nusinowitz, 2006) . The response functions for the treated rd12 eyes (open symbols) are also low pass although they are displaced downward in the graph to lower response amplitudes at most temporal frequencies.
Shown in Fig. 3A , as dashed lines, are the predicted dark-adapted ERG temporal-response functions if amplitudes are scaled by the amount of retinal rescue at all temporal frequencies. V max , derived from the intensity-response functions described above, was used to scale the temporalresponse functions. The response function for the rd12 eyes treated at P18 fall close to predicted function at temporal frequencies below 10 Hz. Above 10 Hz, response amplitudes fall within the normal range (Wlled circles). The data for the 6-month treatment group demonstrate the same pattern, including the inXection at 10 Hz, where responses are somewhat better than predicted. Response amplitudes for the 13-month treatment group fall below predicted values at all temporal frequencies, and the inXection to better than expected amplitudes above 10 Hz, is lost. A discussion of the biphasic response proWle at P18 and 6-months will be deferred until the Section 4.
Each temporal-response function was Wt with a doubleexponential function with four Xoating variables (peak response amplitude, peak temporal frequency, high temporal frequency slope, and low temporal frequency slope) to determine the CFF (Ridder, III & Nusinowitz, 2006) . The CFF was extrapolated by extending the curve to the average noise level for the ERG for each of the three treatment groups. The average noise level was determined by recording the response to a 'blank' trial in the absence of a visual stimulus. The average noise level for the three treatment groups was 1.6, 1.4, and 1.5 V, respectively. Because of the pronounced biphasic response function for the P18 group, only the data above 8 Hz was included in the Wt for this group. Based on this Wt, the dark-adapted CFF for the rd12 mice treated at P18, and 6-and 12-months of age are, 31.6, 18.6, and 20.0 Hz, respectively. The dark-adapted CFF for normal control mice is 26.2 Hz. (r 2 describing the Wt of the equation to the data was 0.96, 0.97, and 0.99 for the three groups of treated rd12 mice, respectively.)
Light-adapted ERG temporal-response functions are shown in Fig. 3B . In normal mice, the light-adapted ERG temporal-response function is consistent with a band-pass Wlter with a peak amplitude at approximately 3 Hz. The response functions for all treated rd12 eyes also demonstrate band-pass Wltering. The response function for eyes treated at P18 are indistinguishable from normal up to approximately 7 Hz, and then depart from the normal curve for higher temporal frequencies. The temporalresponse functions for the mice treated at 6-and 13-months of age are below normal limits at all temporal frequencies. The CFFs for the rd12 mice treated at P18, 6-months, and 13-months are 38.7, 16.5, and 26.5 Hz, respectively. The light-adapted CFF for normal control mice is 41.3 Hz. (The average noise level for the three groups is 1.4, 1.9, and 1.4 V, respectively, with r 2 values describing the Wt of the equation to the data was 0.96, 0.92, and 0.80, respectively.)
VEPs
Dark-adapted VEPs (Fig. 4A ) in normal mice demonstrate band-pass Wltering with a peak response at approximately 2 Hz with a slow roll-oV of response amplitudes on either side of the peak frequency. In contrast, the response functions for the treated rd12 eyes have shifted from bandpass to low-pass Wltering for all treatment groups.
In Fig. 4A , the dashed lines are the normal VEP temporal-response functions scaled by the amount of retinal rescue for each of the three treatment groups as described above. Departures from these predicted responses would be consistent with disruptions of visual pathway processing of temporal information. The data collected for all the treated rd12 eyes fall below expected values at all temporal frequencies except 1.0 Hz. In addition, there is a systematic loss of high temporal-response sensitivity with age of treatment. These observations would suggest a loss of high temporal frequency resolution in the post-retinal visual pathway since this same pattern of high frequency loss was not observed in the ERG responses over the same range of temporal frequencies (see Fig. 3A ). The darkadapted VEP CFFs for the rd12 mice treated at P18, 6-months, and 13-months are 5.3, 6.6, and 3.9 Hz, respectively compared to 7.1 Hz for normal control mice. (The average dark-adapted VEP noise level for the three groups is 3.4, 1.6, and 1.6 V, respectively, with r 2 values of 0.99, 0.94, and 0.99, respectively).
Light-adapted VEP temporal-response functions (Fig. 4B ) are displaced downward in the graph to lower overall response amplitudes, well outside the normal range, and there is a systematic loss of high temporal frequency resolution with age of treatment just as for the darkadapted responses. The light-adapted VEP CFFs for the rd12 mice treated at P18, 6-months, and 13-months are 6.8, 5.9, and 2.4 Hz, respectively. The light-adapted CFF for normal controls is 9.0 Hz. (The average light-adapted VEP noise level for the three groups is 1.5, 3.1, and 3.1 V, respectively, with r 2 values of 0.91, 0.97, and 0.97, respectively.) 
Visual acuity
Visual acuities were determined with the sweep VEP (Ridder, III & Nusinowitz, 2006) . BrieXy, the sweep VEP stimulus consisted of a horizontally oriented sine wave grating of eleven spatial frequencies (0.10, 0.12, 0.16, 0.20, 0.25, 0.32, 0.40, 0.50, 0.63, 0.80, and 0.98 cpd) presented at a temporal reversal rate of 4 Hz. Each spatial frequency was presented for 1 s so that the entire sweep took 12 s (11 spatial frequencies + 1 s pre-adaptation). Forty to Wfty sweeps were recorded for each mouse. Two methods, that depended on the number of data points above noise, were employed to extrapolate the acuity of each mouse (Ridder, III et al., 1998) . The Wrst method utilized a linear Wt to the sweep VEP data. Acuities were determined by Wtting a line between the high spatial frequency data that were above noise and the Wrst spatial frequency that entered noise. The data were determined to be noise if the 95% conWdence intervals for the sweep VEP amplitude data overlapped with zero. The second method of acuity determination was employed if there were no data points between the peak spatial frequency and the noise level. Under these circumstances, the acuity was taken as the highest spatial frequency response that was above noise. Using these methods, the average visual acuity for the normal controls (n D 8), and the rd12 mice treated at P18, 6-months, and 13-months of age, are 0.69 ( §0.08), 0.403 ( §0.14), 0.605 ( §0.13), and 0.10 cycles/ degree, respectively. Equivalent average Snellen visual acuities are 20/870, 20/1489, 20/976, and 20/6000 for the four groups of mice. The estimate of visual acuity for normal controls is consistent with that previously reported using the same methodology (Ridder, III & Nusinowitz, 2006) . Results for individual mice are given in Table 1 .
Discussion
Retinal function after gene replacement therapy in the rd12 mouse model of LCA
As previously described, signiWcant functional rescue was observed in rd12 retinas treated with a sub-retinal injection containing a serotype 5 recombinant adeno-associated virus vector carrying a normal human RPE65 cDNA (Pang et al., 2006) . Rod-mediated ERGs recorded from treated eyes were robust and well formed in comparison to untreated eyes, where ERGs were non-detectable except at the highest stimulus intensities. The extent of functional rescue depended on the timing of therapy consistent with prior studies (Dejneka et al., 2004; Jacobson et al., 2005) ; gene therapy performed early resulted in better retinal rescue. It is important to point out that we have previously demonstrated that ERG functional measurements were correlated with RPE65 expression levels, 11-cis retinaldehyde levels, rhodopsin levels, retinal histology, fundus appearance, presence of all-trans retinal ester in the RPE, and visually guided behavior in rd12 eyes seven months after treatment at P14 (Pang et al., 2006) . In addition, no visual restoration was observed in any control eyes at any time after treatment with AAV5-CBA-hGFP up to 18 months after treatment (Pang et al., 2005b) .
Gene therapy also appeared to better rescue cone-mediated retinal function, but only when treatment occurred early. This conclusion was inferred from comparisons in the dark-and light-adapted temporal response functions. First, for the P18 group, the light-adapted temporal response function (Fig. 3B) overlapped the normal range for the frequency range from 1 to 10 Hz (Fig. 3B ). In contrast, the dark-adapted temporal-response function for this group was only about half that of normal over this same frequency range (Fig. 3A) . Second, the biphasic response function observed under dark-adapted conditions for the earliest treatment group (Fig. 3A) is also consistent with better preservation of cone structure and function. The deXection of the temporal-response function into the normal range for the P18 group at the higher temporal frequencies is due to cone intrusion above 10-15 Hz. Rods cannot resolve temporal modulations above 10-15 Hz (Hecht & Shlair, 1935; Kelly, 1961) , particularly when the stimulus is relatively bright (1.66 cd-s/m 2 ), as in our experiments. The inXection at the higher temporal frequencies is weakened at 6-months, and is absent at 13-months, suggesting that the advantage exhibited by cones at the earliest age of treatment is lost. The observation of better cone rescue may, in part, explain prior Wndings of better vision in daylight than under dim light conditions after gene therapy in the RPE65 null mutation dog (Narfstrom et al., 2003a) .
The observation of detectable cone responses in the mice for which treatment was delayed until 6-and 13-months (Fig. 3B ) was a surprise in light of two recent publications showing a massive loss of cone photoreceptors over the Wrst month of life in Rpe65 ¡/¡tm1Tmr homozygous mice (Chen, Moiseyev, Takahashi, & Ma, 2006; Znoiko et al., 2005) . Nevertheless, cone photoreceptors were still clearly detectable by Xuorescent PNA staining at 4-weeks, the oldest age tested (Chen et al., 2006) and it is conceivable that the initial phase of massive loss is followed by a slower degeneration that would preserve cones for a longer period. This pattern of loss has been shown previously for photoreceptors in the retinal degeneration slow (rds) mouse (Nir, Kedzierski, Chen, & Travis, 2000; Portera-Cailliau, Sung, Nathans, & Adler, 1994) . In addition, the Rpe65 ¡/¡ mouse and the rd12 mouse models of LCA, may not be directly comparable, as these mouse strains have diVerent underlying mutations and diVerent funduscopic phenotypes (Pang et al., 2005a) , and the pattern of cone loss may not be the same for these models. Alternatively, it is possible that the light-adapted responses observed for the older age groups in fact originate from desensitized rods (Seeliger et al., 2001) . Experiments are under way to determine the cellular origin of the light-adapted responses for the older treatment groups.
What are the characteristics of "vision" after retinal rescue in LCA animal models?
While gene replacement therapy has proven successful in restoring retinal function in LCA animal models, less well understood is the status of "vision" in these animals. In humans and animals, limiting sensory input to the visual system leads to severe and often irreversible visual deWcits later in life (Birch & Stager, 1996; Ellemberg, Lewis, Maurer, & Brent, 2000; Kawabata et al., 2003; Lewis et al., 2002; Lewis et al., 1986; Lickey et al., 2004; McMullen, Andrade, & Stahl, 2004; Prusky et al., 2000; Tian & Copenhagen, 2003) . Several studies have included tests of visually guided behavior that presumably reXect the performance of the entire visual system in LCA animal models. In the Briard dog (Narfstrom et al., 2003a) , behavioral tests have included assessment of the ability to navigate a maze and to follow a strong beam of light on the wall in a dimly lit room. More recently, and more quantitatively, visual performance in the Morris water maze under dark-adapted conditions showed that rd12 mice treated in just one eye perform similarly to normally sighted C57BL/6J mice, while untreated rd12 mice perform very poorly (Pang et al., 2006) . Beyond these simple behavioral tasks, little is know about the overall phenomenon of vision in these treated animals. Our experiments were designed to address this question.
Cortical visual function in treated rd12 mice
A comparison of ERG and VEP parameters provided a mechanism for testing the integrity of the visual pathway after gene replacement therapy. Since, ERG and VEP responses possess a constant relation with each other in normal animals, we argue that departures from this relation in treated animals imply dysfunction in the post-retinal visual pathway. This type of analysis is independent of the overall status of retinal function.
Dark-adapted intensity-response functions recorded from the visual cortex were in good agreement with the expectations based on the amount of restored retina (see Fig. 2B ). We used the relative ERG V max amplitudes for the three treatment groups to scale the normal VEP to provide, as a Wrst approximation, the corresponding predicted VEP response functions. The actual VEP data were in close correspondence to predictions (Fig. 2B ) except at the oldest age of treatment where, in addition to amplitude reductions, a pronounced loss of sensitivity (k) was also observed. Overall, the observations for the early treatment ages would suggest a relatively intact visual pathway for the channels carrying high contrast and low temporal frequency luminance information.
The correspondence between actual and predicted response functions is lost when luminance information is modulated at higher temporal frequencies as shown in Fig. 4A . Dark-adapted VEP temporal-response functions were below predicted values at intermediate temporal frequencies for the eyes treated at P18, and at all but 1 Hz for the eyes treated at 6-and 13-months. The systematic loss of high temporal frequency response with age of treatment and the shift in waveform morphology is consistent with loss of function for visual pathways carrying high temporal frequency luminance information.
A similar pattern of results was observed for the lightadapted temporal response functions. Light-adapted VEP temporal-response functions were below normal values at all temporal frequencies and, as with the darkadapted temporal-response VEPs, the departures were greatest for later treatment ages. In addition, there is a systematic shift in waveform morphology with age of treatment. The waveform for normal controls is bimodal, with peaks at approximately 2 and 4 Hz, that is the result of two independent channels having diVerent temporal processing abilities reaching the cortex out of phase (Ridder, III & Nusinowitz, 2006) . A modest suggestion of a bimodal function is apparent in the response function for the mice treated at P18 (Fig. 4B) , but not at 6-and 13-months. Overall, these results would suggest that visual pathways carrying high temporal frequency luminance information are disrupted even at the earliest age of treatment.
Finally, we measured the VEP to stimuli that varied in spatial frequency to estimate visual acuity. Signals that were clearly distinguishable from background noise were detectable for all treatment groups, although the number of spatial frequencies where clear signal was detectable decreased with age of treatment. These results are consistent with prior light microscopy observations (Pang et al., 2005a) . In untreated rd12 eyes, the outer nuclear layer (ONL) appears relatively normal until 3-months of age, although there are obvious voids in the photoreceptor outer-segments that become more pronounced by 7-months of age, when 6-8 layers of cells in the outer nuclear layer (ONL) remain in the mutant retina, and the outer-segments are clearly shorter. These voids in the photoreceptor layer would be expected to progressively reduce spatial resolution and visual acuity.
Conclusion
Consistent with prior studies, early gene replacement therapy resulted in better retinal rescue, and in particular, better rescue of cone-mediated function. Cortical visual function generally corresponded to the degree of retinal rescue for luminance information modulated at low temporal frequencies, except at the oldest age of treatment, where disruption of the visual pathway was suggested. However, processing of high temporal and spatial information at the visual cortex was compromised at all treatment ages, suggesting there are multiple, partially overlapping sensitive periods of development and that the sensitive period for each speciWc visual function may be diVerent (Harwerth & Levi, 1983) . These results provide further support that early treatment in human LCA will have the most hope for optimal visual performance. However, it is diYcult to extrapolate these conclusions to anticipated gene replacement therapy in aVected humans because systematic studies of this sort have not yet been reported in LCA2 patients.
